Cardiovascular Outcomes with Romosozumab Versus Alendronate in Osteoporosis: A Real-World Propensity-Matched Cohort Study (ACR Convergence 2026) - Sep 8, 2026 - Abstract #623; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; No abstract available
Clinical • Real-world • Real-world evidence • Cardiovascular • Osteoporosis • Rheumatology
|